Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 02, 2020 16:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer
December 23, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors
December 18, 2019 08:05 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
November 14, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria
March 11, 2019 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely...